BACKGROUND: The G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) is a common cause of cystic fibrosis (CF). G551D-CFTR is characterized by an extremely low open probability despite its normal trafficking to the plasma membrane. Numerous small molecules have been shown to increase the activity of G551D-CFTR presumably by binding to the CFTR protein. METHODS: We investigated the effect of curcumin, genistein and their combined application on G551D-CFTR activity using the patch clamp technique. RESULTS: Curcumin increased G551D-CFTR whole-cell and single-channel currents less than genistein did at their maximally effective concentrations. However, curcumin further increased the channel activity of G551D-CFTR that had been already maximally potentiated by genistein, up to ~50% of the WT-CFTR level. In addition, the combined application of genistein and curcumin over a lower concentration range synergistically rescued the gating defect of G551D-CFTR. CONCLUSIONS: The additive effects between curcumin and genistein not only support the hypothesis that multiple mechanisms are involved in the action of CFTR potentiators, but also pose pharmaceutical implications in the development of drugs for CF pharmacotherapy.
BACKGROUND: The G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) is a common cause of cystic fibrosis (CF). G551D-CFTR is characterized by an extremely low open probability despite its normal trafficking to the plasma membrane. Numerous small molecules have been shown to increase the activity of G551D-CFTR presumably by binding to the CFTR protein. METHODS: We investigated the effect of curcumin, genistein and their combined application on G551D-CFTR activity using the patch clamp technique. RESULTS:Curcumin increased G551D-CFTR whole-cell and single-channel currents less than genistein did at their maximally effective concentrations. However, curcumin further increased the channel activity of G551D-CFTR that had been already maximally potentiated by genistein, up to ~50% of the WT-CFTR level. In addition, the combined application of genistein and curcumin over a lower concentration range synergistically rescued the gating defect of G551D-CFTR. CONCLUSIONS: The additive effects between curcumin and genistein not only support the hypothesis that multiple mechanisms are involved in the action of CFTR potentiators, but also pose pharmaceutical implications in the development of drugs for CF pharmacotherapy.
Authors: J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou Journal: Science Date: 1989-09-08 Impact factor: 47.728
Authors: Marie E Egan; Marilyn Pearson; Scott A Weiner; Vanathy Rajendran; Daniel Rubin; Judith Glöckner-Pagel; Susan Canny; Kai Du; Gergely L Lukacs; Michael J Caplan Journal: Science Date: 2004-04-23 Impact factor: 47.728
Authors: Do-Yeon Cho; Shaoyan Zhang; Ahmed Lazrak; Jessica W Grayson; Jaime A Peña Garcia; Daniel F Skinner; Dong Jin Lim; Calvin Mackey; Catherine Banks; Sadis Matalon; Bradford A Woodworth Journal: Int Forum Allergy Rhinol Date: 2018-08-27 Impact factor: 3.858
Authors: Zhe Xu; Luísa S Pissarra; Carlos M Farinha; Jia Liu; Zhiwei Cai; Patrick H Thibodeau; Margarida D Amaral; David N Sheppard Journal: J Physiol Date: 2014-03-03 Impact factor: 5.182
Authors: Guido Veit; Dillon F Da Fonte; Radu G Avramescu; Aiswarya Premchandar; Miklos Bagdany; Haijin Xu; Dennis Bensinger; Daniel Stubba; Boris Schmidt; Elias Matouk; Gergely L Lukacs Journal: J Cyst Fibros Date: 2019-10-31 Impact factor: 5.482